Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment
JCO Oncology Practice · 2025
DOI: 10.1200/op-24-00647 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Veronica Mears und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, University Hospitals Cleveland Medical Center, Cleveland, OH. Hauptthemen laut MEDLINE: Capecitabine, Oxaliplatin, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The combination of capecitabine and oxaliplatin (CAPOX) is commonly used in patients with localized colorectal cancer (CRC) receiving curative-intent treatment. Our study aimed to assess the real-world tolerability of CAPOX in a single-institution cohort of patients with localized CRC. METHODS This is a single-institution retrospective study that included patients with localized CRC receiving neoadjuvant or adjuvant CAPOX. The primary end point was completion rate of intended number (obtained by chart review) of CAPOX cycles irrespective of dose levels. Secondary outcome measures included the rate of grade ≥3 adverse events, hospital admission rate, and dose reductions. RESULTS The study included 153 patients with a median age of 61 years; 49% were female and 78.4% had stage III CRC. The proportion of patients (95% CI) who completed all planned CAPOX cycles was 44.4% (36 to 52) in the entire cohort and 34.6% (23 to 45) among female patients. Independent variables associated with treatment completion in multivariable analysis were race, sex, and intended number of cycles. Notably, the therapy completion rates (95% CI) were 55% (43 to 66) and 33% (20 to 45) in patients intended to receive four and eight cycles of CAPOX, respectively. The rate of grade ≥3 adverse events and hospitalization because of CAPOX-related toxicity were 30.7% (95% CI, 23 to 38) and 17.6% (95% CI, 11 to 23), respectively. CONCLUSION This study highlights that a substantial number of patients with localized CRC undergoing curative-intent treatment with CAPOX do not complete the planned cycles of chemotherapy because of toxicity. These findings underscore the need for careful patient selection and appropriate supportive care to optimize the therapeutic benefit of CAPOX in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, University Hospitals Cleveland Medical Center, Cleveland, OH.
- Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH.
- Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH.
- Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH.
ORCID-Profile: Veronica Mears, Nikolas Naleid, Omkar Pawar, Madison Conces, Amit Mahipal, Sakti Chakrabarti
Zitieren
APA
Mears, V., Naleid, N., Pawar, O., Selfridge, J. E., Conces, M., Lumish, M., Bajor, D., Mahipal, A., & Chakrabarti, S. (2025). Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment. JCO Oncology Practice. https://doi.org/10.1200/op-24-00647
Vancouver
Mears V, Naleid N, Pawar O, Selfridge JE, Conces M, Lumish M, et al. Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment. JCO Oncology Practice. 2025. doi:10.1200/op-24-00647
BibTeX
@article{Mears2025,
author = {Mears, Veronica and Naleid, Nikolas and Pawar, Omkar and Selfridge, Jennifer Eva and Conces, Madison and Lumish, Melissa and Bajor, David and Mahipal, Amit and Chakrabarti, Sakti},
title = {Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment},
journal = {JCO Oncology Practice},
year = {2025},
doi = {10.1200/op-24-00647}
}
EUVIMED